Merck Oral COVID Treatment, Molnupiravir, Shown To Reduce Deaths

Published by

Merck and Ridgeback Biotherapeutics are planning to seek emergency authorization for a new oral medication shown to reduce the risk of hospitalization or death by around 50% in mild to moderate COVID-19 cases. The drug, molnupiravir, was tested in a clinical trial, which yielded “compelling” results. The drug reportedly inhibits the replication of the coronavirus within the body. Seven percent of patients treated with molnupiravir in the trial were hospitalized within 29 days. No deaths were reported among patients who received molnupiravir in the 29-day period. Eight deaths were reported amon…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *